Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33
dc.contributor.author | He, Xing | |
dc.contributor.author | Xie, Jun | |
dc.contributor.author | Wang, Yange | |
dc.contributor.author | Fan, Xiaobin | |
dc.contributor.author | Su, Qin | |
dc.contributor.author | Sun, Yue | |
dc.contributor.author | Lei, Nanhang | |
dc.contributor.author | Zhang, Dongmei | |
dc.contributor.author | Gao, Guangping | |
dc.contributor.author | Pan, Weiqing | |
dc.date | 2022-08-11T08:09:50.000 | |
dc.date.accessioned | 2022-08-23T16:45:06Z | |
dc.date.available | 2022-08-23T16:45:06Z | |
dc.date.issued | 2018-03-19 | |
dc.date.submitted | 2018-05-30 | |
dc.identifier.citation | <p>PLoS Pathog. 2018 Mar 19;14(3):e1006957. doi: 10.1371/journal.ppat.1006957. eCollection 2018 Mar. <a href="https://doi.org/10.1371/journal.ppat.1006957">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 1553-7366 (Linking) | |
dc.identifier.doi | 10.1371/journal.ppat.1006957 | |
dc.identifier.pmid | 29554131 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/40620 | |
dc.description.abstract | The type 2 immune response is the central mechanism of disease progression in schistosomiasis, but the signals that induce it after infection remain elusive. Aberrant microRNA (miRNA) expression is a hallmark of human diseases including schistosomiasis, and targeting the deregulated miRNA can mitigate disease outcomes. Here, we demonstrate that efficient and sustained elevation of miR-203-3p in liver tissues, using the highly hepatotropic recombinant adeno-associated virus serotype 8 (rAAV8), protects mice against lethal schistosome infection by alleviating hepatic fibrosis. We show that miR-203-3p targets interleukin-33 (IL-33), an inducer of type 2 immunity, in hepatic stellate cells to regulate the expansion and IL-13 production of hepatic group 2 innate lymphoid cells during infection. Our study highlights the potential of rAAV8-mediated miR-203-3p elevation as a therapeutic intervention for fibrotic diseases. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29554131&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.rights | Copyright: © 2018 He et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Fibrosis | |
dc.subject | MicroRNAs | |
dc.subject | Parasitic diseases | |
dc.subject | Collagens | |
dc.subject | Schistosomiasis | |
dc.subject | Mouse models | |
dc.subject | Liver fibrosis | |
dc.subject | Schistosoma | |
dc.subject | Immunity | |
dc.subject | Immunology of Infectious Disease | |
dc.subject | Parasitic Diseases | |
dc.subject | Parasitology | |
dc.subject | Therapeutics | |
dc.title | Down-regulation of microRNA-203-3p initiates type 2 pathology during schistosome infection via elevation of interleukin-33 | |
dc.type | Journal Article | |
dc.source.journaltitle | PLoS pathogens | |
dc.source.volume | 14 | |
dc.source.issue | 3 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4434&context=oapubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/3423 | |
dc.identifier.contextkey | 12222315 | |
refterms.dateFOA | 2022-08-23T16:45:07Z | |
html.description.abstract | <p>The type 2 immune response is the central mechanism of disease progression in schistosomiasis, but the signals that induce it after infection remain elusive. Aberrant microRNA (miRNA) expression is a hallmark of human diseases including schistosomiasis, and targeting the deregulated miRNA can mitigate disease outcomes. Here, we demonstrate that efficient and sustained elevation of miR-203-3p in liver tissues, using the highly hepatotropic recombinant adeno-associated virus serotype 8 (rAAV8), protects mice against lethal schistosome infection by alleviating hepatic fibrosis. We show that miR-203-3p targets interleukin-33 (IL-33), an inducer of type 2 immunity, in hepatic stellate cells to regulate the expansion and IL-13 production of hepatic group 2 innate lymphoid cells during infection. Our study highlights the potential of rAAV8-mediated miR-203-3p elevation as a therapeutic intervention for fibrotic diseases.</p> | |
dc.identifier.submissionpath | oapubs/3423 | |
dc.contributor.department | Department of Microbiology and Physiological Systems | |
dc.contributor.department | Horae Gene Therapy Center | |
dc.source.pages | e1006957 |